Massachusetts-based Covidien (NYSE:COV) landed European and U.S. regulatory wins for its new Puritan Bennett 980 ventilator.
The 980 is the latest in the Puritan Bennett line, which aims to reduce reliance on sedation by spurring more "natural" breathing. The new system includes tools to customize ventilation levels to individual patients.
The system is cleared for use on patients with ages ranging from neonates to adults, and is also available in Canada in Japan, according to a Covidien press release.
Covidien has been on a regulatory roll in recent months, recently landing FDA nods for its Endo Gia surgical stapler, the modified PillCam Colon and the LigaSure Maryland jaw open/laparoscopic sealer/divider, among other wins.
COV shares were down 1.5% to $70.91 as of about 1:05 p.m. today.
